Immunotherapy 101: How It Trains Your Immune System to Fight Cancer

Recent Trends

Over the past several years, immunotherapy has moved from experimental settings into mainstream oncology practice. Regulatory approvals have expanded beyond melanoma and lung cancer to include a growing list of solid tumors and blood cancers. Combination approaches—pairing checkpoint inhibitors with chemotherapy, targeted therapy, or other immunomodulators—now dominate clinical trial pipelines. Meanwhile, neoadjuvant use before surgery and adjuvant use after surgery are becoming more common, particularly in early-stage disease where the goal is to reduce recurrence risk.

Background

Immunotherapy leverages the body’s own immune system to recognize and attack cancer cells. The core principle is that tumors often evade detection by exploiting “checkpoints”—molecules on T-cells that normally prevent autoimmune reactions. Checkpoint inhibitors (such as PD-1, PD-L1, and CTLA-4 blockers) release these brakes, allowing T-cells to mount a sustained response. Other modalities include:

• CAR-T cell therapy: A patient’s T-cells are harvested, genetically engineered to target a specific tumor antigen, then reinfused.
• Bispecific antibodies: Engineered molecules that bind both a cancer cell and an immune cell, bringing them together for direct killing.
• Cancer vaccines: Designed to present tumor-specific antigens to dendritic cells, priming the immune system against the cancer.
• Oncolytic viruses: Genetically modified viruses that selectively infect and lyse tumor cells while stimulating an immune response.

Each approach aims to overcome the tumor’s ability to suppress immune activity, a process known as immune evasion.

User Concerns

Patients and caregivers often raise several practical questions when considering immunotherapy:

• Side effects: Immune-related adverse events (irAEs) can affect any organ—most commonly skin, gut, liver, and lungs. Severity ranges from mild rash or fatigue to colitis or pneumonitis requiring treatment interruption.
• Eligibility: Not all tumors respond equally. Biomarker testing—such as PD-L1 expression, microsatellite instability (MSI), or tumor mutational burden (TMB)—helps predict likelihood of benefit, though testing standards continue to evolve.
• Duration of treatment: Some patients receive immunotherapy for a fixed period (often 1–2 years), while others continue until progression or unacceptable toxicity.
• Cost and access: Immunotherapy can be expensive, and coverage varies by region and insurance plan. Many programs offer financial assistance, but out-of-pocket costs remain a barrier for some patients.
• Delayed response: Unlike chemotherapy, immunotherapy may take weeks or months to show effect, and some patients experience “pseudoprogression” where tumors appear to grow before shrinking.

Likely Impact

Immunotherapy has already changed the treatment landscape for several cancers, producing durable responses in subsets of patients who previously had limited options. In advanced melanoma and non-small cell lung cancer, for instance, five-year survival rates have improved substantially with checkpoint inhibitors compared to older therapies. The move toward earlier use in disease progression and in combination regimens suggests that immunotherapy will become a standard component across many tumor types. However, the proportion of patients who derive long-term benefit remains modest in certain cancers, and resistance mechanisms—such as loss of antigen presentation or upregulation of alternative checkpoints—continue to limit outcomes.

Key areas of near-term impact include:

• Expansion of adjuvant and neoadjuvant indications, potentially reducing recurrence rates in early-stage disease.
• Integration with precision medicine, where biomarker-matched immunotherapy is paired with targeted agents based on genomic profiling.
• Development of “off-the-shelf” CAR-T products that do not require personalized cell manufacturing, which could reduce costs and waiting times.

What to Watch Next

Several developments are likely to shape the field in the coming months to few years:

• Novel targets and mechanisms: Investigational agents targeting LAG-3, TIGIT, and other checkpoints are advancing through late-stage trials. Bispecific and trispecific antibody platforms are also generating early signals in hematologic and solid tumors.
• Predictive biomarkers: Efforts to refine patient selection beyond PD-L1 and MSI—including tumor microenvironment profiling, circulating tumor DNA analysis, and T-cell receptor sequencing—may improve response rates and reduce unnecessary exposure to toxicity.
• Combination sequencing: Determining the optimal order and timing of immunotherapy with radiation, surgery, and other systemic therapies will be a focus of ongoing and newly launched studies.
• Regulatory and reimbursement shifts: As more indications gain approval, payers and health systems will face pressure to update coverage policies and manage the financial burden of these therapies.
• Patient-centric monitoring: Wearable devices and digital health tools are being tested to track irAEs in real time, potentially improving early intervention and treatment adherence.

Note: Individual patient outcomes depend on cancer type, stage, biomarkers, overall health, and treatment history. Consultation with an oncology team is essential to weigh risks and benefits for any specific case.